<DOC>
	<DOCNO>NCT01670981</DOCNO>
	<brief_summary>This study design assess efficacy , safety tolerability ixmyelocel-T compare placebo ( vehicle control ) administer via transendocardial catheter-based injection patient end stage heart failure due IDCM , reasonable revascularization option ( either surgical percutaneous interventional ) likely provide clinical benefit .</brief_summary>
	<brief_title>An Efficacy , Safety Tolerability Study Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections Subjects With Heart Failure Due Ischemic Dilated Cardiomyopathy ( IDCM )</brief_title>
	<detailed_description>The primary objective study evaluate efficacy ixmyelocel-T compare placebo ( vehicle control ) average per patient number all-cause death , cardiovascular hospital admission , unplanned outpatient emergency department visit treat acute decompensated heart failure , 12 month follow administration investigational product ( IP ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>1 . Males nonpregnant , nonlactating female ; 2 . Age 30 86 year age ; 3 . Diagnosis ischemic dilate cardiomyopathy ; 4 . LVEF ≤ 35 % echocardiogram ; 5 . Symptomatic heart failure NYHA functional class III IV ; 6 . Subject candidate reasonable revascularization procedure produce clinical improvement ; 7 . Subject receive appropriate clinical standard care heart failure therapy , tolerate dictated subject 's current medical condition , least 30 day prior screen ; 8 . Must automatic implantable cardioverter defibrillator ( AICD ) ; 9 . Worsening heart failure hospitalization equivalent within 6 month prior screen , hospitalization equivalent define unplanned outpatient/emergency department visit treatment acute decompensated heart failure ; Nterminal prohormone Btype natriuretic peptide ( NTproBNP ) ≥2000 pg/mL BNP ≥400 pg/mL within 30 day screen ( include screen ) ; 6minute walk test ( 6MWT ) distance ≤400 meter screen ; 10 . Life expectancy least 12 month opinion Investigator ; 11 . LV wall thickness ≥ 7mm ( echocardiogram ) anticipate target injection area ; 12 . Hemodynamic stability without IV vasopressor support device ; 13 . Given medical history concurrent medication , subject acceptable candidate bone marrow aspiration cardiac catheterization transendocardial injection procedure opinion Investigator ; 14 . Willing able comply schedule visit tolerate study procedure . 15 . Voluntarily provide personallysigned dated informed consent . Diseasespecific : 1 . Severe primary valvular heart disease include , limited , aortic valve stenosis insufficiency ; 2 . VAD implantation , heart transplantation , cardiomyoplasty , leave ventricular reduction surgery , cardiac shunt implantation ; 3 . Planned heart failurerelated device intervention ( e.g. , VAD implantation , initial cardiac resynchronization therapy ) plan cardiac procedure ( e.g. , heart transplant , cardiomyoplasty , valvular repair ) ; 4 . Current arrhythmia would prohibit accurate NOGA® electromechanical mapping NOGA®guided injection ; 5 . LV thrombus ( document echocardiography LV angiography ) ; 6 . Myocardial infarction , stroke transient ischemic attack within 3 month prior screen ; 7 . Percutaneous coronary intervention , valvuloplasty , cardiac surgery , major cardiac procedure within 30 day prior screen ; 8 . In opinion Investigator , subject 's left ventricular wall unsuitable transendocardial injection ( due thickness reason ) . Medical History : 9 . Stroke transient ischemic attack ( TIA ) within 3 month screen ; 10 . Hemoglobin A1c ( HbA1c ) ≥ 9 % screening ; 11 . Diabetic subject uncontrolled untreated proliferative retinopathy determine dilate eye exam administer qualified eye care professional per American Diabetes Association guideline ; 12 . Blood clot disorder cause medication ( e.g. , thrombophilia ) ; 13 . Active malignancy ( nonbasal cell ) require surgery , chemotherapy , and/or radiation past 12 month ; 14 . Drug alcohol abuse would interfere subject 's compliance study procedure ; 15 . Allergies equine , porcine , bovine product ; 16 . Body mass index ( BMI ) ≥ 40 kg/m2 screening ; 17 . Established chronic kidney disease ( CKD ) require dialysis ( Stage 5 ) ; estimate creatinine clearance &lt; 15 mL/min screening ; 18 . Subject allergy unable tolerate cardiac image contrast agent ; also inability get good quality echocardiogram image screening ( determined image core lab ) . Laboratory Parameters : 19 . Abnormal laboratory value ( performed central lab ) screening : Platelets &lt; 50,000 μL ; Hemoglobin &lt; 9.0 g/dL ; Aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &gt; 3 time upper limit normal ( ULN ) ; Human immunodeficiency virus 1 ( HIV 1 ) , HIV 2 , syphilis positive ( rapid plasma reagin [ RPR ] ) ; Active hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibodies ; NOTE : Additional lab test may perform per local requirement include limited : hepatitis B core antibody , human T lymphotropic virus I/II . Exclusionary Procedures , Devices , Medication : 20 . Subjects receive antiangiogenic drug ( e.g. , antivascular endothelial growth factor [ VEGF ] ) ; 21 . Chronic exposure cytotoxic therapy oncologic chronic nononcologic reason prior 3 month expect requirement course study ; 22 . Concurrent participation another interventional clinical trial receive experimental intervention within 30 day screen previously expose Aastrom 's ixmyelocel T product previously receive allogeneic cell therapy , autologous cell therapy culture animal protein . 23 . In opinion Investigator , subject unsuitable cellular therapy food/drug allergy , surgical medical condition , clinically significant psychiatric disorder , poor nutritional status , lab abnormality require medical evaluation may interfere investigational product , interfere study result ' interpretation , interfere subject 's ability complete study compromise subject 's safety .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ischemic dilate cardiomyopathy</keyword>
	<keyword>Heart failure</keyword>
	<keyword>ixCELL</keyword>
	<keyword>ixCELL DCM</keyword>
	<keyword>IDCM</keyword>
	<keyword>DCM</keyword>
	<keyword>stem cell</keyword>
	<keyword>MSC</keyword>
	<keyword>cell therapy</keyword>
</DOC>